Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study (Q38453378)
Jump to navigation
Jump to search
scientific article published on March 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study |
scientific article published on March 2013 |
Statements
1 reference
Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study (English)
1 reference
Gregory M Asnis
1 reference
Anjana Bose
1 reference
Carl P Gommoll
1 reference
Changzheng Chen
1 reference
William M Greenberg
1 reference
1 March 2013
1 reference
1 reference
Identifiers
1 reference